SAM
ANAB icon

Shell Asset Management’s AnaptysBio ANAB Stock Holding History

Shell Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,530
Closed -$54K – 1243
2019
Q3 		$54K Sell
1,530
-13
-0.8% -$619 ﹤0.01% 1215
2019
Q2 		$87K Buy
+1,543
New +$111K ﹤0.01% 1177

Other funds holding ANAB

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Shell Asset Management's ANAB Position: Q4 2019 in Review

Shell Asset Management sold out of AnaptysBio (ANAB) in Q4 2019, closing a stake of 1,530 shares — an estimated $54K sold.

Shell Asset Management first reported a position in ANAB in Q2 2019 and held it in 2 quarters. The position peaked at $87K in Q2 2019. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2019.

  • Shell Asset Management reported no remaining AnaptysBio position as of Q4 2019 after selling out during the quarter.
  • Shell Asset Management sold 1,530 AnaptysBio shares in Q4 2019, an estimated $54K.
  • Shell Asset Management first reported a position in AnaptysBio in Q2 2019 and held it in 2 quarters.
  • Shell Asset Management's AnaptysBio position peaked at $87K in Q2 2019.
  • 121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2019.

Based on Shell Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.